These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32862848)

  • 1. Update on CML-Like Disorders.
    Cross NCP
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S101-S102. PubMed ID: 32862848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Szuber N; Orazi A; Tefferi A
    Am J Hematol; 2024 Jul; 99(7):1360-1387. PubMed ID: 38644693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
    Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
    Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
    Tefferi A; Skoda R; Vardiman JW
    Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.
    Sadigh S; Hasserjian RP; Hobbs G
    Curr Opin Hematol; 2020 Mar; 27(2):122-127. PubMed ID: 31904665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematological classification of the chronic myeloid leukaemias.
    Shepherd PC; Ganesan TS; Galton DA
    Baillieres Clin Haematol; 1987 Dec; 1(4):887-906. PubMed ID: 3332855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on eosinophilic disorders.
    Tzankov A; Reichard KK; Hasserjian RP; Arber DA; Orazi A; Wang SA
    Virchows Arch; 2023 Jan; 482(1):85-97. PubMed ID: 36068374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
    Kim SY; Song IC; Kim J; Kwon GC
    Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
    Schoelinck J; Gervasoni J; Guillermin Y; Beillard E; Pissaloux D; Chassagne-Clement C
    Virchows Arch; 2024 May; 484(5):853-857. PubMed ID: 37985498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia.
    Cogswell PC; Morgan R; Dunn M; Neubauer A; Nelson P; Poland-Johnston NK; Sandberg AA; Liu E
    Blood; 1989 Dec; 74(8):2629-33. PubMed ID: 2684296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jak-2 positive myeloproliferative neoplasms.
    Muxí PJ; Oliver AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.
    Yao S; Na L; Liangding H
    Ann Hematol; 2024 Aug; 103(8):3247-3250. PubMed ID: 38888615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differential diagnosis of chronic myeloid leukemia and the related disorders].
    Ashida T; Kanamaru A
    Nihon Rinsho; 2001 Dec; 59(12):2358-62. PubMed ID: 11766339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?
    Oscier DG
    Br J Haematol; 1996 Mar; 92(3):582-6. PubMed ID: 8616021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases.
    Wiedemann LM; Karhi KK; Shivji MK; Rayter SI; Pegram SM; Dowden G; Bevan D; Will A; Galton DA; Chan LC
    Blood; 1988 Feb; 71(2):349-55. PubMed ID: 3276362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.